Evidence map›Paper›PMID 39225047›Full record

ArticleNucleic acids research2024

Eukaryotic initiation factor 4B is a multi-functional RNA binding protein that regulates histone mRNAs.

Ana Quintas, Robert F Harvey, Emilie Horvilleur, Gavin D Garland, Tobias Schmidt, Lajos Kalmar, Veronica Dezi, Alberto Marini, Alexander M Fulton, Tuija A A Pöyry and 6 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ana QuintasMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Robert F HarveyMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Emilie HorvilleurMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Gavin D GarlandMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Tobias SchmidtCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.ORCID 0000-0001-7230-1214
Lajos KalmarMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Veronica DeziMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Alberto MariniMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Alexander M FultonMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Tuija A A PöyryMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Cameron H ColeMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Martin TurnerImmunology Programme, Babraham Institute, Babraham Science Campus, Cambridgeshire CB22 3AT, UK.ORCID 0000-0003-3995-324X
Ritwick SawarkarMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Michael A ChapmanMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.
Martin BushellCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
Anne E WillisMRC Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge CB2 1QW, UK.ORCID 0000-0002-1470-8531

Funding

Beatson Institute for Cancer Research C20673/A30062Biotechnology and Biological Sciences Research Council BB/N017005/1Cancer Research UK 24388Cancer Research UK 29252Cancer Research UK G108392Leukaemia and Lymphoma Research 14032Medical Research Council MC_UU_00025/7
6 · The paper itself

Abstract

RNA binding proteins drive proliferation and tumorigenesis by regulating the translation and stability of specific subsets of messenger RNAs (mRNAs). We have investigated the role of eukaryotic initiation factor 4B (eIF4B) in this process and identify 10-fold more RNA binding sites for eIF4B in tumour cells from patients with diffuse large B-cell lymphoma compared to control B cells and, using individual-nucleotide resolution UV cross-linking and immunoprecipitation, find that eIF4B binds the entire length of mRNA transcripts. eIF4B stimulates the helicase activity of eIF4A, thereby promoting the unwinding of RNA structure within the 5' untranslated regions of mRNAs. We have found that, in addition to its well-documented role in mRNA translation, eIF4B additionally interacts with proteins associated with RNA turnover, including UPF1 (up-frameshift protein 1), which plays a key role in histone mRNA degradation at the end of S phase. Consistent with these data, we locate an eIF4B binding site upstream of the stem-loop structure in histone mRNAs and show that decreased eIF4B expression alters histone mRNA turnover and delays cell cycle progression through S phase. Collectively, these data provide insight into how eIF4B promotes tumorigenesis.

Indexed as

Eukaryotic Initiation FactorsHistonesRNA-Binding ProteinsRNA, MessengerRNA Stability5' Untranslated RegionsBinding SitesCell Line, TumorEukaryotic Initiation Factor-4AHumansLymphoma, Large B-Cell, DiffuseProtein BindingRNA HelicasesTrans-Activators5' Untranslated RegionseIF-4BEukaryotic Initiation Factor-4AEukaryotic Initiation FactorsHistonesRNA-Binding ProteinsRNA HelicasesRNA, MessengerTrans-ActivatorsUPF1 protein, human

Identifiers

PMID39225047
PMCPMC11514447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.